BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 12738309)

  • 1. Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer.
    Miller KL; Marks LB; Sibley GS; Clough RW; Garst JL; Crawford J; Shafman TD
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):355-9. PubMed ID: 12738309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation.
    Videtic GM; Truong PT; Dar AR; Yu EW; Stitt LW
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):709-16. PubMed ID: 14529775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
    J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.
    Schild SE; Bonner JA; Shanahan TG; Brooks BJ; Marks RS; Geyer SM; Hillman SL; Farr GH; Tazelaar HD; Krook JE; Geoffroy FJ; Salim M; Arusell RM; Mailliard JA; Schaefer PL; Jett JR
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):943-51. PubMed ID: 15234027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of accelerated chest irradiation and impact on survival of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer: review of a single institution's experience.
    Ng M; Chong J; Milner A; MacManus M; Wheeler G; Wirth A; Michael M; Ganju V; McKendrick J; Ball D
    J Thorac Oncol; 2007 Jun; 2(6):506-13. PubMed ID: 17545845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
    Turrisi AT; Kim K; Blum R; Sause WT; Livingston RB; Komaki R; Wagner H; Aisner S; Johnson DH
    N Engl J Med; 1999 Jan; 340(4):265-71. PubMed ID: 9920950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of up-front accelerated thoracic radiotherapy combined with chemotherapy and optional up-front prophylactic cranial irradiation in limited small-cell lung cancer. Groupe d'Oncologie Thoracique des Régions Alpines.
    Hügli A; Moro D; Mermillod B; Bolla M; Alberto P; Bonnefoi H; Miralbell R
    J Clin Oncol; 2000 Apr; 18(8):1662-7. PubMed ID: 10764426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
    Komaki R; Shin DM; Glisson BS; Fossella FV; Murphy WK; Garden AS; Oswald MJ; Hong WK; Roth JA; Peters LJ
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):807-11. PubMed ID: 7860392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
    Byhardt RW; Scott C; Sause WT; Emami B; Komaki R; Fisher B; Lee JS; Lawton C
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):469-78. PubMed ID: 9806503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden, 1998-2004.
    Hallqvist A; Rylander H; Björk-Eriksson T; Nyman J
    Acta Oncol; 2007; 46(7):969-74. PubMed ID: 17851846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control.
    Videtic GM; Fung K; Tomiak AT; Stitt LW; Dar AR; Truong PT; Yu EW; Vincent MD; Kocha WI
    Lung Cancer; 2001; 33(2-3):249-58. PubMed ID: 11551420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial.
    Blackstock AW; Bogart JA; Matthews C; Lovato JF; McCoy T; Livengood K; Ho C; White D; Atkins JN; Miller AA
    Clin Lung Cancer; 2005 Mar; 6(5):287-92. PubMed ID: 15845179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study.
    Jeremic B; Shibamoto Y; Acimovic L; Milisavljevic S
    J Clin Oncol; 1997 Mar; 15(3):893-900. PubMed ID: 9060525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
    Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
    Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
    Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
    J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma.
    Bonner JA; Sloan JA; Shanahan TG; Brooks BJ; Marks RS; Krook JE; Gerstner JB; Maksymiuk A; Levitt R; Mailliard JA; Tazelaar HD; Hillman S; Jett JR
    J Clin Oncol; 1999 Sep; 17(9):2681-91. PubMed ID: 10561342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients.
    Jeremić B; Miličić B; Milisavljevic S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1157-63. PubMed ID: 21640518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased metastasis and improved survival with early thoracic radiotherapy and prophylactic cranial irradiation in combined-modality treatment of limited-stage small cell lung cancer.
    Kamath SS; McCarley DL; Zlotecki RA
    Radiat Oncol Investig; 1998; 6(5):226-32. PubMed ID: 9822169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of hypofractionated dose-escalated thoracic radiotherapy for limited-stage small-cell lung cancer.
    Yee D; Halperin R; Hanson J; Nijjar T; Butts C; Smylie M; Reiman T; Roa W
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):466-73. PubMed ID: 16563653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.